Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.

Shu-Kui QinZhendong ChenWei-Jia FangZhenggang RenRuocai XuBaek-Yeol RyooZhiqiang MengYuxian BaiXiaoming ChenXiufeng LiuJuxiang XiaoGwo Fuang HoYimin MaoXin WangJieer YingJianfeng LiWenyan ZhongYu ZhouAbby B SiegelChunyi Hao

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

In patients from Asia with previously treated advanced HCC, pembrolizumab significantly prolonged overall survival and PFS, and ORR was greater versus placebo.

Keyphrases

phase iii
double blind
open label
clinical trial
placebo controlled
phase ii
newly diagnosed
end stage renal disease
ejection fraction
advanced non small cell lung cancer
study protocol
prognostic factors
peritoneal dialysis
randomized controlled trial
patient reported
free survival